GlaxoSmithKline, Britain's biggest drugmaker, renewed its promise to return to growth this year, after failing to deliver a hoped-for sales and margin recovery in 2012. GSK also announced a restructuring of European operations, drug manufacturing and research, designed to save at least 1 billion pounds ($1.57 billion) annually by 2016, while it placed its Lucozade and Ribena drinks brands under strategic review.After putting a number of major drug patent losses behind it, GSK had originally banked on pulling out of its trough in 2012. In the event, sales were held back by larger-than-expected drug price cuts in austerity-hit Europe.Sales in the final quarter of 2012 fell 3 percent to 6.80 billion pounds, generating "core" earnings per share (EPS) up 4 percent at 32.6p pence, the company said on Wednesday.Analysts, on average, had forecast sales of 6.88 billion pounds and core EPS, which excludes certain items, of 31.3p, according to Thomson Reuters I/B/E/S.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI remained unchanged at $30.52. In the past year, the shares have traded as low as $26.20 and as high as $31.18. On average, 762574 shares of TRI exchange hands on a given day and today's volume is recorded at 0.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 0.13% or $0.04/share to $30.40. In the past year, the shares have traded as low as $26.47 and as high as $31.22. On average, 852868 shares of TRI.TO exchange hands on a given day and today's volume is recorded at 1208078.
Source
